Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Medartis completes acquisition of Nextremity Solutions Inc. and announces new US leadership

Basel, Switzerland, 3 May 2022 - Medartis Holding AG (SIX: MED) announced today that it has completed the acquisition of Nextremity Solutions Inc., a strategic commercialisation organisation located...

Read more

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Read more

Medartis has decided not to pursue the convertible bond placement

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The bookbuilding exercise generated a substantial...

Read more

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Ad hoc announcement pursuant to Art. 53 LR

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces...

Read more

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces today the launch of a senior unsecured...

Read more

Medartis shareholders approve all proposals of the Board of Directors

    Ad hoc announcement pursuant to Art. 53 LR
  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a...
Read more

Medartis shareholders approve all proposals of the Board of Directors

  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a large majority
  • Ms. Nadia Tarolli Schmidt...
Read more

Medartis acquires Nextremity Solutions Inc.

We are pleased to announce the aquisition of Nextremity Solutions Inc., a Warsaw (US) based orthopedic company which develops and markets for the treatment of bone fractures and deformities.

Read more

Strong sales growth and further margin improvements – important acquisition to accelerate the US extremities business

  • Total net sales increased by 24.8% year-on-year at CER[1]
  • All regions grew by more than 20% CER – 29% growth in the US and 22% in EMEA
  • Strong growth led to higher margins at all levels  EBITDA...
Read more

Medartis 2021 full-year results presentation

Dear ladies and gentlemen

We are pleased to invite you to our FY 2021 results presentation on 7 March 2022. We will publish our media release, the Annual Report, and the conference presentation on...

Read more